Key Segments:
By Product
-
Ozempic
-
Trulicity
-
Mounjaro
-
Wegovy
-
Rybelsus
-
Saxenda
-
Victoza
-
Zepbound
-
Other Products
By Application
-
Type 2 Diabetes Mellitus
-
Obesity
-
Others
By Route of Administration
-
Parenteral
-
Oral
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Others
Regional Coverage:
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players in the Europe GLP-1 Receptor Agonist Market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca plc, and Boehringer Ingelheim International GmbH, among others.
Key opportunities include expanding NHS and national obesity-treatment pathways and continued manufacturing capacity investment across the region.
The market is driven by expanding national reimbursement approvals, growing clinical guideline support, and gradually widening obesity coverage across member states.
The Ozempic segment dominated the Europe GLP-1 Receptor Agonist Market, accounting for approximately 35.80% share in 2025.
Germany dominated the Europe GLP-1 Receptor Agonist Market in 2025 with a 22.00% share, supported by its large diabetic population and robust statutory insurance system.
